As the world becomes increasingly uncertain, Health Catalyst Inc. (HCAT) offers stability

Health Catalyst Inc. (NASDAQ: HCAT) closed the day trading at 10.04 down -0.99% from the previous closing price of $10.14. In other words, the price has decreased by $-0.10 from its previous closing price. On the day, 1498992 shares were traded. HCAT reached its highest trading level at $10.40 during the session, while it also had its lowest trading level at $9.91.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.



For a better understanding of HCAT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.20 and its Current Ratio is at 5.20. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.48.

Upgrades & Downgrades

On September 13, 2022, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $21 to $11.

Stifel Downgraded its Buy to Hold on August 05, 2022, whereas the target price for the stock was revised from $27 to $16.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 15 when Llewelyn Linda sold 648 shares for $10.99 per share. The transaction valued at 7,122 led to the insider holds 55,865 shares of the business.

Burton Daniel D. bought 90,750 shares of HCAT for $996,970 on Sep 08. The Chief Executive Officer now owns 703,062 shares after completing the transaction at $10.99 per share. On Sep 06, another insider, Orenstein Daniel H., who serves as the General Counsel of the company, sold 2,838 shares for $11.27 each. As a result, the insider received 31,978 and left with 99,608 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 2.19 while its Price-to-Book (P/B) ratio in mrq is 1.15.

Stock Price History:

Over the past 52 weeks, HCAT has reached a high of $54.42, while it has fallen to a 52-week low of $9.89. The 50-Day Moving Average of the stock is 13.41, while the 200-Day Moving Average is calculated to be 21.79.

Shares Statistics:

Over the past 3-months, HCAT traded about 1.21M shares per day on average, while over the past 10 days, HCAT traded about 1.18M shares per day. A total of 53.67M shares are outstanding, with a floating share count of 53.11M. Insiders hold about 3.50% of the company’s shares, while institutions hold 99.00% stake in the company. Shares short for HCAT as of Jul 14, 2022 were 4.03M with a Short Ratio of 2.65, compared to 3.96M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 7.43% and a Short% of Float of 7.47%.

Earnings Estimates

Current recommendations for the stock of the company come from 12 analysts. On average, analysts expect EPS of $-0.1 for the current quarter, with a high estimate of $-0.01 and a low estimate of $-0.27, while EPS last year was $0. The consensus estimate for the next quarter is $-0.14, with high estimates of $-0.04 and low estimates of $-0.31.

Analysts are recommending an EPS of between $-0.09 and $-0.9 for the fiscal current year, implying an average EPS of $-0.38. EPS for the following year is $-0.22, with 14 analysts recommending between $0.2 and $-1.01.

Revenue Estimates

A total of 15 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $293M, while the lowest revenue estimate was $290M, resulting in an average revenue estimate of $290.98M. In the same quarter a year ago, actual revenue was $241.93M, up 20.30% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $349.79M in the next fiscal year. The high estimate is $353.31M and the low estimate is $344.44M. The average revenue growth estimate for next year is up 20.20% from the average revenue estimate for this year.